Title: Circulatory Resistin Levels in Inflammatory Bowel Disease: A Systematic Review and
Meta-Analysis
Version: 0 Date: 01 Jan 2024
Reviewer:  Spyros I. Siakavellas
Reviewer's report:
Many thanks to the authors for submitting their valuable work. This is a well designed review
with rigorous statistical methodology and well presented results.
My comments are as follows:
Main comments:
Your discussion does not go into detail about some of your findings and the potential role of
resistin in the assessment of IBD.
1) For example has there been any comparison with fecal calprotectin?
2) What do you think the role of resistin could be? How confident can you be in its potential
given the high heterogeneity?
3) Are the methods for measuring resistin standardised?
4) Have there been any studies with any of the newer biologic agents?
5) Would you be able to exand a bit on the other conditions affecting resistin levels apart from
BMI?
Furthermore,
6) I noticed that despite the sample size differences the weights in your Forrest plot analysis are
roughly equal. How can this be given that the study from Konrad et al. has the biggest sample
size by far?
7) How do you account for the more modest differences seen in more recent studies?
Minor queries
In the last sentence of the abstract please rephrase as "clues" does not fit with the context. I
would suggest "this indicates that further studies may provide valuable insights for the role of
resistin in the pathogenesis of IBD".
In the first paragraph of the introduction the last sentence can be omitted.
Please replace "circus" with "circle".
In page 15 of the manuscript in the discussion please change "have" after ""meta-analysis" to
"has".
In your discussion paragraphs 2-4 reiterate the points made in the introduction and can be
omitted.
Title: Circulatory Resistin Levels in Inflammatory Bowel Disease: A Systematic Review and
Meta-Analysis
Version: 0 Date: 01 Jan 2024
Reviewer:  Spyros I. Siakavellas
Reviewer's report:
Many thanks to the authors for submitting their valuable work. This is a well designed review
with rigorous statistical methodology and well presented results.
My comments are as follows:
Main comments:
Your discussion does not go into detail about some of your findings and the potential role of
resistin in the assessment of IBD.
1) For example has there been any comparison with fecal calprotectin?
2) What do you think the role of resistin could be? How confident can you be in its potential
given the high heterogeneity?
3) Are the methods for measuring resistin standardised?
4) Have there been any studies with any of the newer biologic agents?
5) Would you be able to exand a bit on the other conditions affecting resistin levels apart from
BMI?
Furthermore,
6) I noticed that despite the sample size differences the weights in your Forrest plot analysis are
roughly equal. How can this be given that the study from Konrad et al. has the biggest sample
size by far?
7) How do you account for the more modest differences seen in more recent studies?
Minor queries
In the last sentence of the abstract please rephrase as "clues" does not fit with the context. I
would suggest "this indicates that further studies may provide valuable insights for the role of
resistin in the pathogenesis of IBD".
In the first paragraph of the introduction the last sentence can be omitted.
Please replace "circus" with "circle".
In page 15 of the manuscript in the discussion please change "have" after ""meta-analysis" to
"has".
In your discussion paragraphs 2-4 reiterate the points made in the introduction and can be
omitted.
Please review this paper.
user
Title: Circulatory Resistin Levels in Inflammatory Bowel Disease: A Systematic Review and
Meta-Analysis
Version: 0 Date: 01 Jan 2024
Reviewer:  Spyros I. Siakavellas
Reviewer's report:
Many thanks to the authors for submitting their valuable work. This is a well designed review
with rigorous statistical methodology and well presented results.
My comments are as follows:
Main comments:
Your discussion does not go into detail about some of your findings and the potential role of
resistin in the assessment of IBD.
1) For example has there been any comparison with fecal calprotectin?
2) What do you think the role of resistin could be? How confident can you be in its potential
given the high heterogeneity?
3) Are the methods for measuring resistin standardised?
4) Have there been any studies with any of the newer biologic agents?
5) Would you be able to exand a bit on the other conditions affecting resistin levels apart from
BMI?
Furthermore,
6) I noticed that despite the sample size differences the weights in your Forrest plot analysis are
roughly equal. How can this be given that the study from Konrad et al. has the biggest sample
size by far?
7) How do you account for the more modest differences seen in more recent studies?
Minor queries
In the last sentence of the abstract please rephrase as "clues" does not fit with the context. I
would suggest "this indicates that further studies may provide valuable insights for the role of
resistin in the pathogenesis of IBD".
In the first paragraph of the introduction the last sentence can be omitted.
Please replace "circus" with "circle".
In page 15 of the manuscript in the discussion please change "have" after ""meta-analysis" to
"has".
In your discussion paragraphs 2-4 reiterate the points made in the introduction and can be
omitted.
assistant